Literature DB >> 8055156

Immunohistochemical detection of p53 protein in cutaneous lesions from transplant recipients harbouring human papillomavirus DNA.

I Pélisson1, Y Chardonnet, S Euvrard, D Schmitt.   

Abstract

Human papillomaviruses (HPV) are thought to be involved in the malignant evolution of cutaneous lesions from transplant recipients. As E6 proteins from potentially oncogenic HPV types degrade p53 tumour suppressor gene product in vitro, we analysed p53 protein status in benign, premalignant and malignant skin lesions from grafted patients, to determine whether HPV may interfere with p53 function. With immunohistochemistry, p53 protein accumulation was detected in 70% of skin lesions from grafted patients. p53 immunoreactivity was confined to basal keratinocytes in benign lesions (warts, condylomas), while suprabasal keratinocytes were also stained in premalignant and malignant skin lesions (precancerous keratoses, squamous cell carcinomas). Multiple HPV carriage was detected with in situ hybridization in benign and malignant skin lesions from transplant recipients: low risk HPV types 1, 2, 6, 11 and potentially oncogenic HPV types 5, 16, 18 were frequently found. There was no clear correlation between p53 detection and the presence of the HPV types under study. The frequent detection of p53 protein in cutaneous lesions from grafted patients is suggestive of p53 protein accumulation interfering with normal function. Our results may reflect the presence of mutated p53 proteins due to the mutagenic effect of ultra-violet (UV), or wild-type p53 protein accumulation in response to UV-induced DNA damage, or may be produced by the interaction with HPV-encoded E6 proteins.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8055156     DOI: 10.1007/bf00195776

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  47 in total

1.  P53 in tumour pathology: can we trust immunocytochemistry?

Authors:  D Wynford-Thomas
Journal:  J Pathol       Date:  1992-04       Impact factor: 7.996

2.  The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines.

Authors:  M Scheffner; K Münger; J C Byrne; P M Howley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

3.  Study of stringency conditions for human papillomavirus DNA detection on cell lines, frozen and paraffin-embedded tissue sections by in situ hybridization with biotinylated probes.

Authors:  I Guerin-Reverchon; Y Chardonnet; M C Chignol; J Thivolet
Journal:  Histochemistry       Date:  1990

4.  Immunologically distinct p53 molecules generated by alternative splicing.

Authors:  N Arai; D Nomura; K Yokota; D Wolf; E Brill; O Shohat; V Rotter
Journal:  Mol Cell Biol       Date:  1986-09       Impact factor: 4.272

5.  Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro.

Authors:  J Bártek; J Bártková; B Vojtĕsek; Z Stasková; A Rejthar; J Kovarík; D P Lane
Journal:  Int J Cancer       Date:  1990-11-15       Impact factor: 7.396

6.  Skin malignancies and human papillomaviruses in renal transplant recipients.

Authors:  S Euvrard; Y Chardonnet; C P Pouteil-Noble; J Kanitakis; J Thivolet; J L Touraine
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

7.  Overexpression of p53 protein in basal cell carcinomas of human skin.

Authors:  C R Shea; N S McNutt; M Volkenandt; J Lugo; P G Prioleau; A P Albino
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

Review 8.  TP53 tumor suppressor gene: a model for investigating human mutagenesis.

Authors:  C Caron de Fromentel; T Soussi
Journal:  Genes Chromosomes Cancer       Date:  1992-01       Impact factor: 5.006

9.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.

Authors:  A D Thor; I I Moore DH; S M Edgerton; E S Kawasaki; E Reihsaus; H T Lynch; J N Marcus; L Schwartz; L C Chen; B H Mayall
Journal:  J Natl Cancer Inst       Date:  1992-06-03       Impact factor: 13.506

10.  Increased expression of mutant forms of p53 oncogene in primary lung cancer.

Authors:  R Iggo; K Gatter; J Bartek; D Lane; A L Harris
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.